Why the study?
Sacubitril/valsartan is a new therapeutic drug for chronic heart failure, but its impact on clinical treatment, cardiac biomarkers, and left ventricular function needed evaluation.
Does sacubitril/valsartan improve clinical effects, cardiac biomarkers, and left ventricular function in patients with chronic heart failure compared to valsartan?
Comparison
Sacubitril/valsartan vs valsartan
Design
Randomized trial
Authors
Loading...
May reduce hs-cTnT/NT-proBNP and improve LAD/LVEDD in CHF; leaves open confirmation in randomized trials.
Does sacubitril/valsartan improve clinical effects, cardiac biomarkers, and left ventricular function in patients with chronic heart failure compared to valsartan?
Sacubitril/valsartan significantly improves clinical symptoms, cardiac biomarkers, and left ventricular function compared to valsartan in patients with chronic heart failure.
Gao et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: